Company Leadership
Characterized by their entrepreneurial spirit and passion for developing next generation diagnostic technologies, Invisible Sentinel's leadership team has the necessary vision, creativity, and business acumen for ensuring the company's value and continued growth.
Benjamin Pascal, MBA, Chief Executive Officer
Benjamin Pascal co-founded Invisible Sentinel in late 2006 and has worked diligently to increase value, advancing the Company’s interests both domestically and abroad. As CEO, Mr. Pascal draws from first-hand experience in the successful development and launch of new clinical devices in the medical device industry, including the coordination of a multi-disciplinary team for the development of B. Braun Medical’s first antimicrobial medical device–for which he was listed as an inventor on a corresponding patent. He was recruited by B. Braun to take part in the company’s Rotational Development Program. As the first American selected, he was nominated to submit for the Global Innovator of the Year from a field of more than 20,000 employees. Previously, Mr. Pascal gained experience at the National Institute for Medical Research in London where he participated in designing a functional cellular vaccine against malaria. He has been on market launch teams and has manufacturing and validation experience with bio-products not unlike Invisible Sentinel’s technology. Mr. Pascal graduated with honors from The George Washington University with concentrations in Biology and Political Science and completed his MBA at Lehigh University.
Nicholas Siciliano, Chief Operating Officer
Since co-founding Invisible Sentinel in 2006, Mr. Siciliano has been aggressively working to advance the Company’s research initiatives and optimize operations of its laboratory facilities. As COO, Mr. Siciliano draws on his more than 10 years of experience in research and lab management and his strong background in Microbiology and Immunology. Mr. Siciliano previously studied host-pathogen interactions with an emphasis on bacterial pathogenesis and the link between innate and adaptive immunity. He has successfully developed several antibody-based assays and has consulted on numerous projects in the fields of bacteriology, immunology, and antibody design. He was instrumental in designing our novel flow‐thru system and is the lead author on all of Invisible Sentinel’s non-provisional, PCT, and provisional patent applications. Mr. Siciliano received his scientific training at Villanova University (Bachelors of Chemistry) and began his biomedical research career at the University of Pennsylvania Medical School—where he spent several years performing independent research and managing a bacterial pathogenesis lab.
Louis Leong, PhD, Director of Research and Development
Dr. Leong brings to Invisible Sentinel nearly 20 years of experience in Research and Development, in the rapidly growing and challenging life science industry. He was instrumental in designing, developing and launching several multi-million dollar biotechnology product lines for Invitrogen and Life Technologies. The innovative technologies that Dr. Leong developed resulted in product lines of cloning, gene expression, in vivo imaging, fluorescent detection, immunology and diagnostic kits. Working with large pharmaceutical companies and academic luminaries, Dr. Leong was also successful in incorporating key Invitrogen technologies and products into their critical work flows.
Dr. Leong's leadership helped to develop an international presence for Life Technologies by establishing successful R&D and Manufacturing capabilities in Bangalore, India. His technology development and transfer skills allowed for significant reductions in overhead and improved margins of multi-million dollar product lines. Dr. Leong has been listed as an inventor on four patents and has a list of publications spanning two decades. He received his Ph.D. in Molecular Biology from the Institute of Molecular and Cell Biology at the National University of Singapore, and received his Bachelor’s of Science in Biochemistry from Queen’s University in Canada. Dr. Leong was a Post Doctoral Fellow at the University of California-Irvine California, conducting research in virology and translational systems.
